Evidence map›Paper›PMID 35887931›Full record

ReviewJournal of clinical medicine2022

Main Barriers to the Introduction of a Home Haemodialysis Programme in Poland: A Review of the Challenges for Implementation and Criteria for a Successful Programme.

Dana Kendzia, Federica Lima, Jacek Zawierucha, Ellen Busink, Christian Apel, Jacek Stanislaw Malyszko, Pawel Zebrowski, Jolanta Malyszko

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Hemodiafiltration at Home: A Single Centre Experience Reviewing Safety, Efficacy, and Implementation.Hemodialysis international. International Symposium on Home Hemodialysis · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Dana KendziaFresenius Medical Care Deutschland GmbH, Else Kroener Str. 1, 61352 Bad Homburg, Germany.
Federica LimaFresenius Medical Care Deutschland GmbH, Else Kroener Str. 1, 61352 Bad Homburg, Germany.
Jacek ZawieruchaFresenius Medical Care Poland, 60-118 Poznań, Poland.ORCID 0000-0001-7980-4842
Ellen BusinkFresenius Medical Care Deutschland GmbH, Else Kroener Str. 1, 61352 Bad Homburg, Germany.
Christian ApelFresenius Medical Care Deutschland GmbH, Else Kroener Str. 1, 61352 Bad Homburg, Germany.
Jacek Stanislaw Malyszko1st Department of Nephrology and Transplantology, Medical University of Białystok, Żurawia 14, 15-540 Białystok, Poland.
Pawel ZebrowskiDepartment of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.
Jolanta MalyszkoDepartment of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.ORCID 0000-0001-8701-8171
Fresenius Medical Care (Germany) · DEMedical University of Białystok · PLMedical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHome dialysis in Poland is restricted to the peritoneal dialysis (PD) modality, with the majority of dialysis patients treated using in-centre haemodialysis (ICHD). Home haemodialysis (HHD) is an additional home therapy to PD and provides an attractive alternative to ICHD that combines dialysis with social distancing; eliminates transportation needs; and offers clinical, economic, and quality of life benefits. However, HHD is not currently provided in Poland. This review was performed to provide an overview of the main barriers to the introduction of a HHD programme in Poland. MAIN

findingsThe main high-level barrier to introducing HHD in Poland is the absence of specific health legislation required for clinician prescribing of HHD. Other barriers to overcome include clear definition of reimbursement, patient training and education (including infrastructure and experienced personnel), organisation of logistics, and management of complications. Partnering with a large care network for HHD represents an alternative option to payers for the provision of a new HHD service. This may reduce some of the barriers which need to be overcome when compared with the creation of a new HHD service and its supporting network due to the pre-existing infrastructure, processes, and staff of a large care network.

conclusionsProvision of HHD is not solely about the provision of home treatment, but also the organisation and definition of a range of support services that are required to deliver the service. HHD should be viewed as an additional, complementary option to existing dialysis modalities which enables choice of modality best suited to a patient's needs.

Indexed as

chronic kidney disease (CKD)COVID-19end-stage renal disease (ESRD)home haemodialysis (HHD)in-centre haemodialysis (ICHD)large care networksperitoneal dialysis (PD)renal replacement therapy (RRT)

Identifiers

PMID35887931
PMCPMC9321469
OpenAlexW4285730702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.